Upgrade to SI Premium - Free Trial

FDA approves Pfizer's (PFE) talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancer

October 16, 2018 11:28 AM
On October 16, 2018, the Food and Drug Administration approved talazoparib (TALZENNA, Pfizer Inc.), a poly (ADP-ribose) polymerase (PARP) inhibitor ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA

Next Articles